What is the optimal duration of ADT in high-risk prostate cancer treated with RT+ADT?  

Nabib et al. presented "Final Results" of the 18 vs. 36 month ADT trial for high-risk M0 prostate cancer in Chicago during ASCO 2017. This trial has the potential to be practice changing, since most men receive 2+ years of ADT during RT-ADT for high-risk disease. 630 patients were randomized and OS ...

While the study was not designed to test non-inferiority (but rather superiority) there is small chance that it is not powered adequately to truly ascertain non-inferiority of 18 as compared to 36 mos of ADT.  That being said, I am very happy to see that with additional f/u (median now 9.4 as o...

Cohort studies are great. They influence practice guidelines for managing patients who look similar to those evaluated. When prospective, and randomized, they provde us with scientifically sound data that are the most convincing. As such, they are classified as "the highest level of evidence". Howev...

Dr. Nabid acknowledged in the panel discussion, that further analysis incorporating testosterone levels may be helpful. These data were apparently collected, and may be presented ahead in the manuscript. ( @Anthony V. D'Amico posed the question: after 18 months, perhaps PSA rise may be non-clinicall...